Edgewise Therapeutics, Inc. 8K

Edgewise Therapeutics completed the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion, refocusing the company on its cardiovascular pipeline and materially bolstering its cash position.

On July 13, 2026, Edgewise Therapeutics, Inc. announced the completion of its previously disclosed transaction under which Servier acquired sevasemten and Edgewise’s muscular dystrophy business for $1.55 billion in upfront cash and up to $1.1 billion in additional regulatory and commercial milestone payments, for total potential consideration of $2.65 billion. Servier obtained all rights and related assets for sevasemten, and the core employee group supporting the muscular dystrophy business received offers to transition to Servier. The deal significantly strengthens Edgewise’s balance sheet and marks a strategic shift to a cardiovascular-focused company centered on its pipeline candidates EDG-7500, EDG-15400, and EDG-003, with the company stating that upfront proceeds, together with existing cash, are expected to fully fund EDG-7500 development through potential approval and support further advancement of its cardiovascular programs, including planned Phase 3 and Phase 2 trials for EDG-7500 and EDG-15400, respectively.

Filing Facts

CIK

1710072

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-082902

Alert Tier

8